Momenta Pharmaceuticals Reports First Quarter 2017 Financial Results
02. Mai 2017 08:00 ET
|
Momenta Pharmaceuticals, Inc.
--Company reports Glatopa® 20 mg product revenues of $23 million, a 58% increase over the same period in 2016----Ended the first quarter with a strong cash position of $434 million--CAMBRIDGE, Mass.,...
Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 42nd Annual Health Care Conference
26. April 2017 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 26, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Date of First Quarter 2017 Financial Results Conference Call and Webcast
18. April 2017 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 18, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
Momenta Pharmaceuticals to Webcast Presentation at the Cowen and Company 37th Annual Health Care Conference
28. Februar 2017 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results
21. Februar 2017 07:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2016. ...
Momenta Pharmaceuticals Announces Time Change for Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast
17. Februar 2017 18:05 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), announced today that is has changed the time for its fourth quarter and year end 2016 earnings...
Momenta Pharmaceuticals Announces FDA Warning Letter to Contracted Glatopa® (glatiramer acetate injection) Fill/Finish Manufacturer
17. Februar 2017 18:00 ET
|
Momenta Pharmaceuticals, Inc.
Approval of the Glatopa 40 mg ANDA will be dependent on resolution of Pfizer facility compliance issues Warning letter does not restrict the production or shipment of Glatopa 20 mg CAMBRIDGE,...
Momenta Pharmaceuticals Announces HSR Clearance for Collaboration and License Agreement with CSL
17. Februar 2017 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 17, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs,...
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2016 Financial Results Conference Call and Webcast
07. Februar 2017 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
Momenta Pharmaceuticals to Webcast Presentation at the Leerink Partners 6th Annual Global Healthcare Conference
01. Februar 2017 08:00 ET
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...